8/5/04

L3 STRUCTURE UPLOADED

=> d l3
L3 HAS NO ANSWERS
L3 STR



G1 C,O,S,N

Structure attributes must be viewed using STN Express query preparation.

=> sl3 ful
SL3 IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> s l3 ful
FULL SEARCH INITIATED 14:56:29 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 25407 TO ITERATE

100.0% PROCESSED 25407 ITERATIONS 11 ANSWERS
SEARCH TIME: 00.00.01

L4 11 SEA SSS FUL L3

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	315.04	315.25

10/741326

FILE 'CAPLUS' ENTERED AT 14:56:35 ON 05 AUG 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 5 Aug 2004 VOL 141 ISS 6
FILE LAST UPDATED: 3 Aug 2004 (20040803/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l4
L5 3 L4

=> d abs bib hitstr 1-3

L5 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN
AB The present invention relates to implantable surgical medical devices having coatings comprising one or more compds. that inhibit TNF-α converting enzyme (TACE), more particularly, stents having coatings comprising TACE inhibitors. A TACE inhibitor is effective in reducing restenosis.
AN 2004:512993 CAPLUS
DN 141:76809
TI Anti-inflammatory coatings for implantable medical devices containing a TACE inhibitor
IN Dodd, John H.
PA USA
SO U.S. Pat. Appl. Publ., 14 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004120977	A1	20040624	US 2003-732570	20031210
PRAI	US 2002-434007P	P	20021217		
	US 2003-482273P	P	20030625		

IT **461664-66-4 461664-67-5 461664-79-9**
RL: DEV (Device component use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(anti-inflammatory coatings for implantable medical devices containing TACE inhibitor)
RN 461664-66-4 CAPLUS
CN 1-Oxaspiro[4.4]nonane-7-carboxamide, N-hydroxy-8-[[4-[[2-(1-methylethyl)-1H-benzimidazol-1-yl]methyl]benzoyl]amino]-, (5R,7S,8R)- (9CI) (CA INDEX

NAME)

Absolute stereochemistry.



RN 461664-67-5 CAPLUS
CN 1-Oxaspiro[4.4]nonane-7-carboxamide, N-hydroxy-8-[[4-[[2-(trifluoromethyl)-1H-benzimidazol-1-yl]methyl]benzoyl]amino]-, (5R,7S,8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 461664-79-9 CAPLUS
CN 1-Oxaspiro[4.4]nonane-7-carboxamide, 8-[[4-[[2-(1,1-difluoroethyl)-1H-benzimidazol-1-yl]methyl]benzoyl]amino]-N-hydroxy-, (5R,7S,8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



L5 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN
AB This invention relates to a method of treating inflammatory diseases in a mammal comprising administering to the mammal a therapeutically effective amount of a combination of: (i) at least one TACE inhibitor, (ii) one or more anti-inflammatory agents selected from the group consisting of: selective COX-2 inhibitors, interleukin-1 antagonists, dihydroorotate synthase inhibitors, p38 MAP kinase inhibitors, TNF-α inhibitors, TNF-α sequestration agents, and methotrexate. The invention also relates to compns. and kits containing the same.
AN 2003:950052 CAPLUS

8/5/04

DN 140:13040
TI Combined use of TACE inhibitors and COX2 inhibitors as anti-inflammatory agents
IN Duan, Jingwu
PA USA
SO U.S. Pat. Appl. Publ., 20 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2003225054	A1	20031204	US 2003-453036	20030603
PRAI US 2002-385656P	P	20020603		

OS MARPAT 140:13040
IT **461664-66-4 461664-67-5 461664-79-9**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combined use of TACE inhibitors and COX2 inhibitors as anti-inflammatory agents)
RN 461664-66-4 CAPLUS
CN 1-Oxaspiro[4.4]nonane-7-carboxamide, N-hydroxy-8-[[4-[[2-(1-methylethyl)-1H-benzimidazol-1-yl]methyl]benzoyl]amino]-, (5R,7S,8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 461664-67-5 CAPLUS
CN 1-Oxaspiro[4.4]nonane-7-carboxamide, N-hydroxy-8-[[4-[[2-(trifluoromethyl)-1H-benzimidazol-1-yl]methyl]benzoyl]amino]-, (5R,7S,8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 461664-79-9 CAPLUS
CN 1-Oxaspiro[4.4]nonane-7-carboxamide, 8-[[4-[[2-(1,1-difluoroethyl)-1H-benzimidazol-1-yl]methyl]benzoyl]amino]-N-hydroxy-, (5R,7S,8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





L5 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN

AB Novel spiro-cyclic β-amino acid derivs. C-B-NR1CO-Z-Ua-Xa-Ya-Za [C-B represents a spiro-cyclic ring system, where rings B and C are 3-13 membered carbocycles or heterocycles; ring B is bonded to NR1 via ACR2aCR2b-; A = alkanoyl, CO2H or ester, CH2CO2H, CONHOH, SH, CH2SH, etc.; R2a = H, alkyl, OH, alkoxy, an amino group, S(O)p (p = 0-2), etc.; R2b = H, alkyl; R1 = H, alkyl, Ph, PhCH2; Z is absent or is a carbocycle or heterocycle; Ua is absent or is O, NH, alkylimino, CO, CO2, O2C, CONH, S(O)p, etc.; Xa is absent or is alkylene, alkenylene, or alkynylene; Ya is absent or is O, NH, alkylimino, S(O)p, CO; Za = H, carbocycle, or heterocycle] or their pharmaceutically-acceptable salts were prepared as matrix metalloproteinases (MMP), TNF-α converting enzyme (TACE), and/or aggrecanase inhibitors. Thus, (7S,8R)-N-hydroxy-8-[[4-[(2-methyl-4-quinolinyl)methoxy]benzoyl]amino]-1,4-dioxaspiro[4.4]nonane-7-carboxamide was prepared by a multistep synthesis starting from (1S,2R)-1-Me cis-1,2,3,6-tetrahydrophthalate. The latter underwent sequential esterification with benzyl alc., oxidative ring opening with KMnO4, and recyclization with Ac2O/NaOAc to yield intermediate benzyl Me (1S,2R)-4-oxo-1,2-cyclopentanedicarboxylate.

AN 2002:736225 CAPLUS

DN 137:262960

TI Preparation of spiro-cyclic β-amino acid derivatives as inhibitors of matrix metalloproteinases and TNF-α converting enzyme (TACE)

IN Ott, Gregory R.; Chen, Xiaotao; Duan, Jingwu; Voss, Matthew E.

PA Bristol-Myers Squibb Company, USA

SO PCT Int. Appl., 187 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002074738	A2	20020926	WO 2002-US7652	20020312
	WO 2002074738	A3	20030403		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2003087882	A1	20030508	US 2002-96804	20020312
	US 6720329	B2	20040413		

EP 1373199 A2 20040102 EP 2002-728458 20020312
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
US 2004132693 A1 20040708 US 2003-741326 20031218
PRAI US 2001-275898P P 20010315
US 2002-96804 A3 20020312
WO 2002-US7652 W 20020312

OS MARPAT 137:262960

IT **461664-65-3P 461664-66-4P 461664-67-5P**
461664-68-6P 461664-70-0P 461664-71-1P
461664-72-2P 461664-75-5P 461664-76-6P
461664-77-7P 461664-79-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of spiro-cyclic β-amino acid derivs. as inhibitors of matrix metalloproteinases and TNF-α converting enzyme (TACE))

RN 461664-65-3 CAPLUS

CN 1-Oxaspiro[4.4]nonane-7-carboxamide, N-hydroxy-8-[[4-[(2-methyl-1H-benzimidazol-1-yl)methyl]benzoyl]amino]-, (5R,7S,8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 461664-66-4 CAPLUS

CN 1-Oxaspiro[4.4]nonane-7-carboxamide, N-hydroxy-8-[[4-[[2-(1-methylethyl)-1H-benzimidazol-1-yl]methyl]benzoyl]amino]-, (5R,7S,8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 461664-67-5 CAPLUS
CN 1-Oxaspiro[4.4]nonane-7-carboxamide, N-hydroxy-8-[[4-[[2-(trifluoromethyl)-1H-benzimidazol-1-yl]methyl]benzoyl]amino]-, (5R,7S,8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 461664-68-6 CAPLUS
CN 1-Oxaspiro[4.4]nonane-7-carboxamide, 8-[[4-[[2-(1,1-dimethylethyl)-1H-benzimidazol-1-yl]methyl]benzoyl]amino]-N-hydroxy-, (5R,7S,8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 461664-70-0 CAPLUS
CN 1-Oxaspiro[4.4]nonane-7-carboxamide, 8-[[4-[[2-(difluoromethyl)-1H-benzimidazol-1-yl]methyl]benzoyl]amino]-N-hydroxy-, (5R,7S,8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 461664-71-1 CAPLUS

CN 1-Oxaspiro[4.4]nonane-7-carboxamide, 8-[[4-[(2-cyclopropyl-1H-benzimidazol-1-yl)methyl]benzoyl]amino]-N-hydroxy-, (5R,7S,8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 461664-72-2 CAPLUS
CN 1-Oxaspiro[4.4]nonane-7-carboxamide, 8-[[4-[(2-cyclobutyl-1H-benzimidazol-1-yl)methyl]benzoyl]amino]-N-hydroxy-, (5R,7S,8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 461664-75-5 CAPLUS
CN 1-Oxaspiro[4.4]nonane-7-carboxamide, N-hydroxy-8-[[4-[[2-(1-methylcyclopropyl)-1H-benzimidazol-1-yl]methyl]benzoyl]amino]-, (5R,7S,8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 461664-76-6 CAPLUS
CN 1-Oxaspiro[4.4]nonane-7-carboxamide, 8-[[4-[[2-(fluoromethyl)-1H-

benzimidazol-1-yl]methyl]benzoyl]amino]-N-hydroxy-, (5R,7S,8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 461664-77-7 CAPLUS
CN 1-Oxaspiro[4.4]nonane-7-carboxamide, 8-[[4-[[2-(1-fluoro-1-methylethyl)-1H-benzimidazol-1-yl]methyl]benzoyl]amino]-N-hydroxy-, (5R,7S,8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



RN 461664-79-9 CAPLUS
CN 1-Oxaspiro[4.4]nonane-7-carboxamide, 8-[[4-[[2-(1,1-difluoroethyl)-1H-benzimidazol-1-yl]methyl]benzoyl]amino]-N-hydroxy-, (5R,7S,8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



8/5/04

Uploading C:\Stnexp4 corrupted\QUERIES\10741326.str



chain nodes :
10 11 12
ring nodes :
1 2 3 4 5 6 7 8 9 13 14 15 16 17 18 22 23 24 25 26 27 28 29
30
chain bonds :
10-11 11-12 11-13
ring bonds :
1-2 1-5 2-3 3-4 3-6 3-9 4-5 6-7 7-8 8-9 13-14 13-18 14-15 15-16 16-17
17-18 22-23 22-27 23-24 24-25 25-26 26-27 26-28 27-30 28-29 29-30
exact/norm bonds :
1-2 1-5 2-3 3-4 3-6 3-9 4-5 6-7 7-8 8-9 10-11 11-12 11-13 26-28 27-30
28-29 29-30
normalized bonds :
13-14 13-18 14-15 15-16 16-17 17-18 22-23 22-27 23-24 24-25 25-26 26-27

G1:C,O,S,N

G2:O,S

G3:C,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:CLASS 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 21:CLASS
22:Atom 23:Atom
24:Atom 25:Atom 26:Atom 27:Atom 28:Atom 29:Atom 30:Atom

L6 STRUCTURE UPLOADED

=> d l6
L6 HAS NO ANSWERS

8/5/04

L6 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s l6 ful
FULL SEARCH INITIATED 15:01:30 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 78213 TO ITERATE

100.0% PROCESSED 78213 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

L7 0 SEA SSS FUL L6

=> file registry

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	156.26	490.14

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-2.21

FILE 'REGISTRY' ENTERED AT 15:02:39 ON 05 AUG 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 3 AUG 2004 HIGHEST RN 721883-12-1
DICTIONARY FILE UPDATES: 3 AUG 2004 HIGHEST RN 721883-12-1

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading C:\Stnexp4 corrupted\QUERIES\10741326.str

8/5/04



chain nodes :
10 11 12
ring nodes :
1 2 3 4 5 6 7 8 9 13 14 15 16 17 18 22 23 24 25 26 27 28 29
30
chain bonds :
10-11 11-12 11-13
ring bonds :
1-2 1-5 2-3 3-4 3-6 3-9 4-5 6-7 7-8 8-9 13-14 13-18 14-15 15-16 16-17
17-18 22-23 22-27 23-24 24-25 25-26 26-27 26-28 27-30 28-29 29-30
exact/norm bonds :
1-2 1-5 2-3 3-4 3-6 3-9 4-5 6-7 7-8 8-9 10-11 11-12 11-13 26-28 27-30
28-29 29-30
normalized bonds :
13-14 13-18 14-15 15-16 16-17 17-18 22-23 22-27 23-24 24-25 25-26 26-27

G1:C,O,S,N

G2:O,S

G3:C,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:CLASS 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 21:CLASS
22:Atom 23:Atom
24:Atom 25:Atom 26:Atom 27:Atom 28:Atom 29:Atom 30:Atom

L8 STRUCTURE UPLOADED

=> d l8
L8 HAS NO ANSWERS
L8 STR

8/5/04

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s l8
SAMPLE SEARCH INITIATED 15:03:04 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 25084 TO ITERATE

4.0% PROCESSED 1000 ITERATIONS 0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 492212 TO 511148
PROJECTED ANSWERS: 0 TO 0

L9 0 SEA SSS SAM L8

=> file registry
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 0.84 490.98

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE ENTRY TOTAL SESSION
CA SUBSCRIBER PRICE 0.00 -2.21

FILE 'REGISTRY' ENTERED AT 15:03:53 ON 05 AUG 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 3 AUG 2004 HIGHEST RN 721883-12-1
DICTIONARY FILE UPDATES: 3 AUG 2004 HIGHEST RN 721883-12-1

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading C:\Stnexp4 corrupted\QUERIES\10741326.str

8/5/04



chain nodes :
10 11 12
ring nodes :
1 2 3 4 5 6 7 8 9 13 14 15 16 17 18 22 23 24 25 26 27 28 29
30
chain bonds :
10-11 11-12 11-13
ring bonds :
1-2 1-5 2-3 3-4 3-6 3-9 4-5 6-7 7-8 8-9 13-14 13-18 14-15 15-16 16-17
17-18 22-23 22-27 23-24 24-25 25-26 26-27 26-28 27-30 28-29 29-30
exact/norm bonds :
1-2 1-5 2-3 3-4 3-6 3-9 4-5 6-7 7-8 8-9 10-11 11-12 11-13 26-28 27-30
28-29 29-30
normalized bonds :
13-14 13-18 14-15 15-16 16-17 17-18 22-23 22-27 23-24 24-25 25-26 26-27

G1:C,O,S,N

G2:O,S

G3:C,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:CLASS 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 21:CLASS
22:Atom 23:Atom
24:Atom 25:Atom 26:Atom 27:Atom 28:Atom 29:Atom 30:Atom

L10 STRUCTURE UPLOADED

=> d l10
L10 HAS NO ANSWERS
L10 STR

10/741326

8/5/04

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s l10 ful
FULL SEARCH INITIATED 15:04:19 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 149211 TO ITERATE

100.0% PROCESSED 149211 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

L11 0 SEA SSS FUL L10

=> file registry

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	155.84	646.82

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-2.21

FILE 'REGISTRY' ENTERED AT 15:04:53 ON 05 AUG 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 3 AUG 2004 HIGHEST RN 721883-12-1
DICTIONARY FILE UPDATES: 3 AUG 2004 HIGHEST RN 721883-12-1

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading C:\Stnexp4 corrupted\QUERIES\10741326.str

8/5/04



chain nodes :
10 11 12
ring nodes :
1 2 3 4 5 6 7 8 9 13 14 15 16 17 18 22 23 24 25 26 27 28 29
30
chain bonds :
10-11 11-12 11-13
ring bonds :
1-2 1-5 2-3 3-4 3-6 3-9 4-5 6-7 7-8 8-9 13-14 13-18 14-15 15-16 16-17
17-18 22-23 22-27 23-24 24-25 25-26 26-27 26-28 27-30 28-29 29-30
exact/norm bonds :
1-2 1-5 2-3 3-4 3-6 3-9 4-5 6-7 7-8 8-9 10-11 11-12 11-13 26-28 27-30
28-29 29-30
normalized bonds :
13-14 13-18 14-15 15-16 16-17 17-18 22-23 22-27 23-24 24-25 25-26 26-27

G1:C,O,S,N

G2:O,S

G3:C,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:CLASS 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 21:CLASS
22:Atom 23:Atom
24:Atom 25:Atom 26:Atom 27:Atom 28:Atom 29:Atom 30:Atom

L12 STRUCTURE UPLOADED

=> d l12
L12 HAS NO ANSWERS
L12 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s l12 ful
FULL SEARCH INITIATED 15:05:18 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 152757 TO ITERATE

100.0% PROCESSED 152757 ITERATIONS 6 ANSWERS
SEARCH TIME: 00.00.02

L13 6 SEA SSS FUL L12

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	155.42	802.24

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-2.21

FILE 'CAPLUS' ENTERED AT 15:05:25 ON 05 AUG 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 5 Aug 2004 VOL 141 ISS 6
FILE LAST UPDATED: 3 Aug 2004 (20040803/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l13
L14 1 L13

=> d abs bib hitstr

L14 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN
AB Novel spiro-cyclic β-amino acid derivs. C-B-NR1CO-Z-Ua-Xa-Ya-Za [C-B represents a spiro-cyclic ring system, where rings B and C are 3-13 membered carbocycles or heterocycles; ring B is bonded to NR1 via ACR2aCR2b-; A = alkanoyl, CO2H or ester, CH2CO2H, CONHOH, SH, CH2SH, etc.; R2a = H, alkyl, OH, alkoxy, an amino group, S(O)p (p = 0-2), etc.; R2b = H, alkyl; R1 = H, alkyl, Ph, PhCH2; Z is absent or is a carbocycle or heterocycle; Ua is absent or is O, NH, alkylimino, CO, CO2, O2C, CONH,

S(O)p, etc.; Xa is absent or is alkylene, alkenylene, or alkynylene; Ya is absent or is O, NH, alkylimino, S(O)p, CO; Za = H, carbocycle, or heterocycle] or their pharmaceutically-acceptable salts were prepared as matrix metalloproteinases (MMP), TNF-α converting enzyme (TACE), and/or aggrecanase inhibitors. Thus, (7S,8R)-N-hydroxy-8-[[4-[(2-methyl-4-quinolinyl)methoxy]benzoyl]amino]-1,4-dioxaspiro[4.4]nonane-7-carboxamide was prepared by a multistep synthesis starting from (1S,2R)-1-Me cis-1,2,3,6-tetrahydrophthalate. The latter underwent sequential esterification with benzyl alc., oxidative ring opening with KMnO4, and recyclization with Ac2O/NaOAc to yield intermediate benzyl Me (1S,2R)-4-oxo-1,2-cyclopentanedicarboxylate.

AN 2002:736225 CAPLUS
DN 137:262960
TI Preparation of spiro-cyclic β-amino acid derivatives as inhibitors of matrix metalloproteinases and TNF-α converting enzyme (TACE)
IN Ott, Gregory R.; Chen, Xiaotao; Duan, Jingwu; Voss, Matthew E.
PA Bristol-Myers Squibb Company, USA
SO PCT Int. Appl., 187 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002074738	A2	20020926	WO 2002-US7652	20020312
	WO 2002074738	A3	20030403		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2003087882	A1	20030508	US 2002-96804	20020312
	US 6720329	B2	20040413		
	EP 1373199	A2	20040102	EP 2002-728458	20020312
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	US 2004132693	A1	20040708	US 2003-741326	20031218
PRAI	US 2001-275898P	P	20010315		
	US 2002-96804	A3	20020312		
	WO 2002-US7652	W	20020312		

OS MARPAT 137:262960
IT **461664-69-7P 461664-74-4P 461664-78-8P**
461664-80-2P 461664-81-3P 461664-82-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of spiro-cyclic β-amino acid derivs. as inhibitors of matrix metalloproteinases and TNF-α converting enzyme (TACE))
RN 461664-69-7 CAPLUS
CN 1-Oxaspiro[4.4]nonane-7-carboxamide, N-hydroxy-8-[[4-[(2-methyl-1H-indol-3-yl)methyl]benzoyl]amino]-, (5R,7S,8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 461664-74-4 CAPLUS
CN 1-Oxaspiro[4.4]nonane-7-carboxamide, N-hydroxy-8-[[4-[(2-methyl-1H-indol-1-yl)methyl]benzoyl]amino]-, (5R,7S,8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 461664-78-8 CAPLUS
CN 1-Oxaspiro[4.4]nonane-7-carboxamide, N-hydroxy-8-[[4-(1H-indol-3-ylmethyl)benzoyl]amino]-, (5R,7S,8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 461664-80-2 CAPLUS
CN 1-Oxaspiro[4.4]nonane-7-carboxamide, 8-[[4-[(2,3-dimethyl-1H-indol-1-yl)methyl]benzoyl]amino]-N-hydroxy-, (5R,7S,8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 461664-81-3 CAPLUS
CN 1-Oxaspiro[4.4]nonane-7-carboxamide, 8-[[4-[(2-ethyl-1H-indol-1-yl)methyl]benzoyl]amino]-N-hydroxy-, (5R,7S,8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 461664-82-4 CAPLUS
CN 1-Oxaspiro[4.4]nonane-7-carboxamide, N-hydroxy-8-[[4-[[2-(trifluoromethyl)-1H-indol-1-yl]methyl]benzoyl]amino]-, (5R,7S,8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


CF3
N
O
HO
N
H
HN
O
S R
R
O